Last Price
40.25
Today's Change
+0.25 (0.62%)
Day's Change
39.50 - 40.45
Trading Volume
1,993,348
Market Cap
142 Million
Shares Outstanding
355 Million
Avg Volume
2,658,500
Avg Price (50 Days)
45.42
Avg Price (200 Days)
93.03
PE Ratio
-4.47
EPS
-0.09
Earnings Announcement
30-Apr-2024
Previous Close
40.00
Open
40.06
Day's Range
39.5 - 40.45
Year Range
39.5 - 166.98
Trading Volume
1,993,348
1 Day Change
0.62%
5 Day Change
-2.99%
1 Month Change
-7.47%
3 Month Change
-22.97%
6 Month Change
-63.41%
Ytd Change
-65.60%
1 Year Change
-59.34%
3 Year Change
-81.79%
5 Year Change
31.97%
10 Year Change
-65.89%
Max Change
-96.31%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.